91˿Ƶ

AMR Inaugural Innovation Summit Advertisement

AMR Centre newsletter
For the latest in
AMR news & events

2021 91˿Ƶ AMR Innovation Summit

Antimicrobials in the era of AMR Virtual event November 19th 2021 at 14:00 EDT

During World Antimicrobial Awareness Week (Nov. 18-24 2021), the 91˿Ƶ AMR Centre and Innovation + Partnership office are hosting the inaugural 91˿Ƶ AMR Innovation Summit, a virtual event aimed at discussing antimicrobial R&D and building collaborations and partnerships between 91˿Ƶ scientists and non-academic stakeholders.

Program

  • 14:00-14:30 Keynote speaker Erin Duffy, PhD | “Building a Portfolio of Products to Address AMR” (public event)
  • 14:30-15:00 Panel discussion (public event)
  • 15:00-16:00 Industry-Academic networking event (private event)

Photo Erin Duffy Keynote speaker Erin Duffy, PhD, Chief of Research & Development, CARB-X

CARB-X is a global non-profit partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria. CARB-X funds the world’s largest early development pipeline of new antibiotics, vaccines, rapid diagnostics, and other products to prevent, diagnose and treat life-threatening bacterial infections. Prior to CARB-X, she worked at Melinta Therapeutics (fka Rib-X Pharmaceuticals) where she became EVP, Chief Scientific Officer. Erin began her career in the Central Research Labs of Pfizer as a computational chemist and structural biologist.

Panel Discussion Challenges and Opportunities for Antimicrobial Research and Development in the Era of AMR
With experts from industry and academia.

Confirmed panelists:
Erin Duffy, PhD, Chief of Research & Development, CARB-X
Joseph Mancini, PhD, Head of Pharmacology and Biologics, Senior Director at adMare BioInnovations
Nicolas Moitessier, PhD, Professor in Chemistry (91˿Ƶ), co-founder of Molecular Forecaster
Martin Schmeing, PhD, Professor in Biochemistry (91˿Ƶ), Director of Centre for Structural Biology
Makeda Semret, MSc, MD, FRCPC, Associate Professor of Medicine, Infectious Diseases and Medical Microbiology (91˿Ƶ); Lead, Antimicrobial Stewardship Program (MUHC)
Christopher Tan, PhD, Director, BD&L, Infectious Diseases & Vaccines, Merck & Co., Inc.

If you have any questions, please contact us at amrcentre [at] mcgill.ca

Back to top